1.Comparison of the Clinical Outcomes Between Cisplatin-Chemoradiotherapy and Radiotherapy Alone in Patient with Cervical Cancer.
Jee Hyun LEE ; Jung NAM ; Jin Hee RHU ; Jeong Ja KIM ; Hee Kyung LIM ; Yong Jae YANG ; Ki Sung RYU ; Ku Taek HAN ; Hun Young LEE ; Soo Pyung KIM
Korean Journal of Gynecologic Oncology and Colposcopy 1998;9(3):259-265
We compared the therapeutic effects of concomitant chemoradiotherapy (CRT) using cisplatin to single radiotherapy (RT) in uterine cervical cancer. 34 cases of non-operable uterine cervical cancer were reviewed retrospectively from Mar, 1993 to May, 1996 in St. Mary' s Hospital. The patients were randomly selected to compare the effects of both methods. 22 patients were included in CRT group and 12 patients in RT group. The results were as follows: 1. The decrease of tumor size was not significant (2.17 cm in CRT and 1.95 cm in RT) (p=0.61), but the number of responders of CRT group was larger than that of RT group significantly (p<0.05). 2. The tumor markers showed no significant difference between CRT and RT groups (p>0.05) 3. The overall survival rate showed no difference between two groups (p>0.05). The disease-free survivals for 38 months were 17.02% in CRT and 11.36% in RT, but it was not significant (p>0.05). In conclusion, concomitant chemoradiotherapy showed better rate of response, but size of tumor decrease and tumor markers showed no difference. CRT might improve the overall survival and disease-free survival, although it was not significant in this study. The clinical significance of CRT remains to be determined in large randomized clinical trial.
Chemoradiotherapy
;
Cisplatin
;
Disease-Free Survival
;
Humans
;
Radiotherapy*
;
Retrospective Studies
;
Survival Rate
;
Biomarkers, Tumor
;
Uterine Cervical Neoplasms*
2.A Study on the Leptin Concentrations in Maternal and Cord Blood.
Hee Joong LEE ; Gi Hong KIM ; Sang Woo RHU ; Dong Choon PARK ; Jae Hoon KIM ; Dong Jin KWON ; Sa Jin KIM ; Young Ok LEW ; Dae Hoon KIM
Korean Journal of Obstetrics and Gynecology 2004;47(1):5-9
OBJECTIVE: In this study, We investigated the circulating level of leptin in the maternal and cord serum to estimate the effect of leptin on the fetal growth. METHODS: In full-term pregnancy, right after delivery, we calculated the concentration of leptin in the maternal and cord serum by using an immunoassay. we studied the relation between these value, the maternal BMI at the time of delivery, the neonatal body weight. RESULTS: At the time of delivery, mean concentration of maternal leptin and cord leptin showed 335.7 pg/ml and 118.3 pg/ml and there was no statistical significance between them. Mean concentration of matenal leptin has positive relation with maternal body weight. but not to neonatal weight. Mean concentration of cord serum leptin has a positive relation with neonatal weight. There was a correlation between the maternal BMI and the neonatal weight at the time of delivery. We evaluated the mean leptin level of neonates of two different sexes, that difference did not show a statistically significant level. CONCLUSION: In this study, no correlation was found between concentration of maternal leptin and cord leptin. These data suggested that the cord serum leptin has a positive relation with fetal growth independantly, regardless of maternal leptin and maternal BMI.
Body Weight
;
Fetal Blood*
;
Fetal Development
;
Humans
;
Immunoassay
;
Infant, Newborn
;
Leptin*
;
Pregnancy
3.Analysis of Factors Influencing Secondary Bleeding after Hemorrhoidectomy.
Do Yeon HWANG ; Yoo Jin KIM ; Ji Eun CHUNG ; Jong Ho LEE ; Hee Chul CHANG ; Jae Hyun RHU ; Hyun Shig KIM ; Jong Kyun LEE
Journal of the Korean Society of Coloproctology 2002;18(6):369-372
PURPOSE: Secondary bleeding is an inevitable and a troublesome complication of hemorrhoidectomy. This study analyzed the factors related to secondary bleeding after hemorrhoidectomy. METHODS: A total of 14,062 patients received a hemorrhoidectomy from Apr. 1999 to Apr. 2001. A retrospective study of 83 patients with secondary bleeding was done. At first, the doctors were divided into two groups. In one group, each doctor had performed more than 500 hemorrhoidectomies; in the other groups, each doctor had performed less than 500 hemorrhoidectomies. The incidence of secondary bleeding of the two groups was compared. Then, 155 patients without secondary bleeding were randomly selected as a control group. Clinical aspects and laboratory data were compared with those of the bleeding group. RESULTS: The total incidence of secondary bleeding was 0.6%. The incidence for the group with experienced doctors was 0.5%, that for the other group was 1.3%. When bleeding patients were compared with the control group, the proportion of patients who received a blood transfusion within 1 week before operation was 12.1% in the bleeding group and 2.6% in the control group. The postoperative WBC count was increased more in the bleeding group. The percentage treated with metronidazole was 12% compared with 25.3% in the control group. The incidences of bleeding according to operation sites were 19.6% in the right anterior, 12.2% in the left lateral, 10.9% in the right posterior, and 8.4% in the posterior portion. CONCLUSIONS: Secondary bleeding after a hemorrhoidectomy is more prevalent with less experienced doctors, recent history of blood transfusion, less use of metronidazole, and specific location of the hemorrhoid, such as the right anterior and the left lateral site of the hemorrhoid pile.
Blood Transfusion
;
Hemorrhage*
;
Hemorrhoidectomy*
;
Hemorrhoids
;
Humans
;
Incidence
;
Metronidazole
;
Retrospective Studies
4.Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients
Sang Jin KIM ; Jinsoo RHU ; Seo Hee LEE ; Jong Man KIM ; Gyu-Seong CHOI ; Kyunga KIM ; Jae-Won JOH
Annals of Surgical Treatment and Research 2020;99(3):180-187
Purpose:
Tenofovir disoproxil fumarate is accepted as an effective and tolerable drug for treatment of HBV, similar to entecavir. However, there are some concerns about the nephrotoxicity of tenofovir. The aim of this study is to compare the renal-function change of liver recipients who received tenofovir or entecavir for HBV.
Methods:
Among 468 patients with HBV who underwent liver transplantation at Samsung Medical Center between January 2008 and December 2015, the patients treated with tenofovir (n = 39) or entecavir (n = 429) were reviewed retrospectively.Baseline characteristics and renal-function change after 1 month, 1 year, and 2 years were compared. Propensity-score matching was performed for 37 patients using tenofovir and 132 patients using entecavir. We also analyzed risk factors of renal dysfunction.
Results:
Age, preoperative creatinine, estimated glomerular filtration rate (e-GFR), and hepatic encephalopathy score showed statistical difference between the tenofovir and entecavir groups. The proportion of patients with ‘decreased renal function (e-GFR < 60 mL/min/1.73 m 2 )’ was higher in the tenofovir group than in the entecavir group (33.3% vs. 12.4% at postoperative one year, p < 0.005). After propensity-score matching, there was no statistical difference in preoperative characteristics. Postoperative 1-, 2-, and 3-year e-GFR and creatinine showed no statistical difference in either group. On multivariate analysis, only preoperative high e-GFR showed a protective effect on renal-function change (odds ratio, 0.97; p < 0.001), and there was no aggravating factor.
Conclusion
Tenofovir disoproxil fumarate does not induce renal dysfunction in liver-transplanted patients with HBV more than does entecavir.
5.Establishment of Cord Blood Stem Cell Bank in Korea.
Kyung Duk PARK ; Hyeong Soo CHOI ; Hyeon Jin PARK ; Ki Woong SUNG ; Bin CHO ; Hoon KOOK ; Kyung Ha RHU ; Young Ho LEE ; Hee Young SHIN ; Heung Sik KIM ; Hack Ki KIM ; Kun Soo LEE ; Tai Ju HWANG ; Hyo Seop AHN ; Yong Mook CHOI
Korean Journal of Pediatric Hematology-Oncology 1999;6(1):105-114
PURPOSE: The needs of stem cell transplantation are increasing in Korea under the circumstance of medical insurance coverage since 1996. But allogeneic bone marrow transplants have the limitation in acquisition of matched donor because of small number of siblings in modern society. Although unrelated stem cell transplantations were made possible in Korea with the establishment of Korean Marrow Donor Program, less than one third of patients who need stem cell transplantation are seeking the matched donors through this program and it still takes too much time and efforts. In this clinical setting, cord blood offers an exciting alternative to traditional sources of stem cells. To implement the widespread clinical use of cord blood stem cells, it is necessary to establish the cord blood bank from which stem cell specimens are obtained. METHODS: To establish the cord blood bank in Korea, we started to develop the proper methods to obtain the cord bloods. Various ways of collecting the cord bloods, separation of red blood cells and storage methods were tried and the standard recommendations were made. RESULTS: Mean volume of collected umbilical cord blood was above 70mL by open or closed method in vaginal delivery and cesarean section. Among the RBC depletion methods by using 3% gelatin, Ficoll-Hypaque, or modified Ficoll-Hypaque method, 3% gelatin sedimentation showed the best result in viability and number of mononuclear cells(MNC), CD34+ cell, and day 14 CFU-GM. The recovery rate after freezing-thawing MNC was higher in the group of using 10% DMSO and programmed freezer starting from 4degrees C than in the group of using mixed with DMSO and hydroxyethyl starch and without programmed freezer. Nine patients underwent cord blood transplantation until December 1998. Among them, 6 patients showed the long-term successful engraftment. CONCLUSION: We have developed simple, efficient, and reproducible methods for collection, processing, and storage of cord blood to establish the cord blood bank. There are some administrative issues including the legal and financial problems that possibly will be resolved by the support of the government and the medical team.
Bone Marrow
;
Cesarean Section
;
Dimethyl Sulfoxide
;
Erythrocytes
;
Female
;
Fetal Blood*
;
Gelatin
;
Granulocyte-Macrophage Progenitor Cells
;
Humans
;
Insurance Coverage
;
Korea*
;
Pregnancy
;
Siblings
;
Starch
;
Stem Cell Transplantation
;
Stem Cells*
;
Tissue Donors